Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.

doi:10.1007/s00280-016-3146-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.

Cancer chemotherapy and pharmacology - 1 Nov 2016

Oda Naohiro, Hotta Katsuyuki, Yoshioka Hiroshige, Kudo Kenichiro, Ichihara Eiki, Kato Yuka, Ninomiya Kiichiro, Minami Daisuke, Ninomiya Takashi, Kubo Toshio, Ohashi Kadoaki, Sato Akiko, Takigawa Nagio, Tabata Masahiro, Tanimoto Mitsune, Kiura Katsuyuki

Abstract excerpt

BACKGROUND: Being overweight has been reported to induce hepatic dysfunction during cytotoxic chemotherapy. Severe hepatic dysfunction can also be observed during gefitinib monotherapy, leading to interrupted or discontinued treatment. However, whether being overweight is a risk factor during gefitinib therapy is unknown. METHODS: We retrospectively reviewed 183 Japanese patients with epidermal growth factor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Mass Index

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemical and Drug Induced Liver Injury

Share to ErbB Receptors

Share to Gefitinib

Share to Liver Function Tests

Share to Overweight

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 27590708
DOI: 10.1007/s00280-016-3146-z

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.PMID 27590708Read ↗

Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.Semantic proximity Read ↗

Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation.Semantic proximity Read ↗

High Body Mass Index Was Related to Favorable Therapeutic Efficacy of Epidermal Growth Factor Receptor Targeted Therapy in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Semantic proximity Read ↗

Prevalence and risk factors of malnutrition according to GLIM criteria in patients with hepatocellular carcinoma: a single-center cross-sectional studySemantic proximity Read ↗

Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.Semantic proximity Read ↗

Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].Semantic proximity Read ↗

Weight change and Impact on prognosis in patients with Advanced Non-small Cell Lung Cancer with Concomitant diabetes mellitus treated with SGLT2 inhibitorsSemantic proximity Read ↗

Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.Semantic proximity Read ↗

Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.